55 straight years of rising dividends for Johnson & Johnson

55 straight years of rising dividends for Johnson & Johnson

A Member of Pat McKeough’s Inner Circle recently requested his opinion on one of the best known consumer stocks in North America.

Johnson & Johnson gets almost half of its revenue from its pharmaceutical business. Investors can underestimate the risk of drug stocks, says Pat, due… Read More

Q: Dear Pat: Johnson & Johnson seems to be a widely recommended stock. Please, may I have your analysis?

A: Johnson & Johnson, $135.11, symbol JNJ on New York (Shares outstanding: 2.7 billion; Market cap: $364.8 billion; www.jnj.com), operates through three major businesses:

Pharmaceutical (47% of revenue) makes anti-infective, antipsychotic, contraceptive, dermatological and gastrointestinal drugs;

Medical devices and diagnostics (35%) sells equipment for joint reconstruction and… Read More

Growth Stocks: Johnson & Johnson plans for a growth spurt

Growth Stocks: Johnson & Johnson plans for a growth spurt

Both revenue and earnings continue to grow for this leading maker of prescription drugs and consumer products. But still, there are risks.
JOHNSON & JOHNSON (symbol JNJ on New York; www.jnj.com) operates through three major businesses:
Pharmaceutical (47% of revenue) makes anti-infective, antipsychotic, contraceptive, dermatological and gastrointestinal… Read More

Q: Dear Pat: Johnson & Johnson seems to be one of those stocks I regularly hear about. Please, may I have your analysis?

A: Johnson & Johnson, $124.44, symbol JNJ on New York (Shares outstanding: 2.7 billion; Market cap: $337.1 billion; www.jnj.com), operates through three major businesses:
Pharmaceutical (47% of revenue) makes anti-infective, antipsychotic, contraceptive, dermatological and gastrointestinal drugs;
Medical devices and diagnostics (35%) sells equipment for joint reconstruction and… Read More